SRPTbenzinga

Sarepta Provides Update On UK Dosing in ENVISION Study Of ELEVIDYS For Treatment Of Duchenne Muscular Dystrophy. Company Received Feedback From The Medicines And Healthcare Products Regulatory Agency In U.K That Dosing May Continue Uninterrupted In Envisi

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on May 21, 2025 by benzinga